Nerandomilast (PDE4B Inhibitor): Reshaping IPF Treatment

1. PDE4 Family Biology: Four Subtypes and Their Links to Fibrosis

Phosphodiesterase 4 (PDE4) is a family of enzymes that degrade the intracellular second messenger cAMP. The family comprises four subtypes — PDE4A, PDE4B, PDE4C, and PDE4D — all cAMP-specific, yet differing markedly in tissue distribution and physiological roles.

• PDE4A: Broadly expressed in the brain and immune cells. Moderate contribution to inflammatory signaling.
• PDE4B: Highly expressed in macrophages, neutrophils, and fibroblasts. Directly governs TNF-alpha production and NF-kappaB signaling, making it a key driver of both inflammation and fibrosis.
• PDE4C: Expression is limited, and its pharmacological significance is considered low.
• PDE4D: Highly expressed in the central nervous system (particularly the medullary emetic center) and smooth muscle. PDE4D inhibition potently triggers nausea and vomiting.

Roflumilast (Daliresp), approved for COPD, inhibits PDE4A–D non-selectively. While it demonstrated anti-inflammatory efficacy, severe nausea and vomiting driven by PDE4D inhibition became the dose-limiting toxicity, effectively precluding administration at doses sufficient for antifibrotic activity. This "tolerability barrier" has been the single greatest obstacle to applying PDE4 inhibition in fibrotic diseases for over a decade.

2. Molecular Design of Nerandomilast: The PDE4B-Selectivity Breakthrough

Nerandomilast (BI 1015550, trade name Jascayd), developed by Boehringer Ingelheim, is an oral small molecule with approximately 9-fold selectivity for PDE4B over PDE4D. This selectivity profile enables meaningful pharmacological activity at the site of pulmonary fibrosis (PDE4B) while largely bypassing the emetic center (PDE4D).

Antifibrotic Mechanism of Action

Nerandomilast exerts antifibrotic effects through multiple complementary pathways:

1. Direct suppression of fibroblast activity via cAMP elevation: PDE4B inhibition raises intracellular cAMP in lung fibroblasts, suppressing TGF-beta-induced collagen production, alpha-SMA expression (myofibroblast differentiation), and cell proliferation.
2. Anti-inflammatory effects: Elevated cAMP in macrophages and neutrophils reduces production of pro-inflammatory cytokines — TNF-alpha, IL-1beta, and IL-6 — breaking the chronic inflammatory loop that sustains fibrosis.
3. Complementarity with existing therapies: Because its mechanism is distinct from nintedanib and pirfenidone (receptor tyrosine kinase inhibition / TGF-beta signal suppression), pharmacologically independent additive effects are expected.

3. Clinical Trial Data: From Phase 2 to FDA Approval

Phase 2 Trial (NEJM 2023)

Richeldi et al. reported results of a randomized, double-blind trial comparing nerandomilast (BI 1015550) 18 mg twice daily with placebo over 12 weeks in 147 IPF patients (Richeldi L et al., N Engl J Med 2022;386(23):2178-2187, PMID 35569036).

• Primary endpoint (FVC change at 12 weeks): Nerandomilast +5.7 mL vs. placebo -81.7 mL (difference: ~88 mL without background antifibrotic). FVC decline was completely arrested in the nerandomilast arm, suggesting disease stabilization.
• Concomitant background therapy: Comparable FVC preservation was observed in patients already receiving pirfenidone or nintedanib, providing the first evidence that add-on therapy is feasible — a landmark finding.
• Tolerability: Incidence of nausea and vomiting was low, clinically validating the PDE4B-selectivity concept.

Phase 3 Trial (FIBRONEER-IPF)

FIBRONEER-IPF was a 52-week randomized, double-blind, placebo-controlled trial enrolling 1,177 IPF patients across 36 countries. 77.7% of patients were on background therapy with nintedanib or pirfenidone. All arms (nerandomilast 9 mg, 18 mg, and placebo) were dosed twice daily.

• Primary endpoint (annual rate of FVC decline over 52 weeks):
  • Nerandomilast 18 mg: -114.7 mL/year
  • Nerandomilast 9 mg: -138.6 mL/year
  • Placebo: -183.5 mL/year
  • 18 mg vs. placebo: difference +68.8 mL, 38% relative reduction in FVC decline (p < 0.001)
  • 9 mg vs. placebo: difference +44.9 mL, 24% relative reduction in FVC decline (p = 0.02)
• Subgroup analyses: Consistent FVC preservation was observed regardless of background antifibrotic use — a clinically critical finding demonstrating additional benefit even for patients already on standard-of-care therapy.
• Safety profile: The most common adverse event was diarrhea (41.3% in the 18 mg arm, 31.1% in the 9 mg arm, 16.0% in the placebo arm — most events Grade 1–2). Severe nausea and vomiting were infrequent. Long-term tolerability was judged to be favorable.
• Limitations of secondary endpoints: The composite endpoint of acute exacerbation, respiratory hospitalization, and death did not reach statistical significance. This has been attributed to the constraints of the 52-week observation period and statistical power; longer-term follow-up data are awaited.

Regulatory Status

• US FDA (IPF): Approved on October 7, 2025 (trade name Jascayd). The first new IPF therapy to join the existing antifibrotics, including as add-on therapy.
• US FDA (PPF): Indication expanded to progressive pulmonary fibrosis (PPF) on December 19, 2025.
• European EMA: Under centralized review (EMEA/H/C/006405; approval anticipated in H1–mid 2026)^[7].
• Japan PMDA: Submission process in progress (Boehringer Ingelheim has stated that "filings in additional geographies will follow"; not yet listed on the PMDA's public approval registry at the time of writing)^[8].

4. Positioning Among Existing Therapies: Toward a Three-Pillar IPF Regimen

Parameter	Nintedanib (Ofev)	Pirfenidone (Esbriet)	Nerandomilast (Jascayd)
Mechanism	Receptor tyrosine kinase inhibition (VEGFR, FGFR, PDGFR)	TGF-beta signal suppression / antioxidant	Selective PDE4B inhibition (cAMP elevation)
FVC decline reduction	~50% (vs. placebo)	~40–50% (vs. placebo)	~38% (vs. placebo, on background therapy)
Key adverse effects	Diarrhea (60–70%), hepatotoxicity	Photosensitivity, decreased appetite, nausea	Diarrhea (41.3% at 18 mg), mostly Grade 1–2
Combination use	Limited data with pirfenidone	Limited data with nintedanib	Efficacy confirmed in combination with both nintedanib and pirfenidone
Route / frequency	Oral (twice daily)	Oral (three times daily)	Oral (twice daily)
Year of approval	2014	2014	2025

A key differentiating feature of nerandomilast is that the pivotal Phase 3 program (FIBRONEER-IPF) stratified randomization by background antifibrotic use and demonstrated consistent FVC preservation in both layers. Its mechanism is independent from current standard-of-care agents, minimizing the risk of pharmacological antagonism, and tolerability in the combination setting has been favorable (note that the pirfenidone co-administration regimen is restricted to the 18 mg twice-daily dose due to a drug-drug interaction).

Notably, the IPF pipeline also includes candidates with yet other mechanisms — such as the LPA1 receptor antagonist BMS-986278. The integrin (αvβ6/αvβ1) inhibitor bexotegrast (PLN-74809) was previously considered a combination candidate, but Pliant Therapeutics discontinued its IPF development in June 2025 after the DSMB observed an increase in disease-progression events in the BEACON-IPF Phase 2b/3 trial (development in PSC and other indications continues separately). Whether multi-drug combination regimens will be established as a standard of care for IPF remains an open question requiring longer-term follow-up and additional combination trials, with nerandomilast positioned as a leading candidate within that landscape.

5. Preclinical Implications: Strategies for Evaluating PDE4B Inhibitors

Proper evaluation of PDE4B inhibitor efficacy demands careful attention to preclinical model selection and study design.

Recommended Models and Dosing Protocols

The bleomycin-induced pulmonary fibrosis model (mouse) is the first-line choice, but dosing timing is critical.

• Therapeutic dosing protocol (treatment initiation from Day 7 onward) is recommended: Days 0–7 post-bleomycin represent the inflammatory phase, with transition to fibrosis from Day 7 onward. To accurately assess antifibrotic efficacy of a PDE4B inhibitor, treatment should begin at Day 7–10 when fibrosis is being established. Prophylactic dosing from Day 0 confounds anti-inflammatory and antifibrotic effects and does not reflect the clinical treatment setting.
• Assessment timepoint: Day 21–28 is recommended, when fibrosis has reached a plateau and the efficacy evaluation window is widest.

Combination Efficacy Studies

Given that the clinical value of nerandomilast lies in its add-on benefit, it is strongly recommended to include a nintedanib combination arm in preclinical studies. A 4-arm design — nintedanib alone, nerandomilast alone, combination, and vehicle — enables evaluation of additive or synergistic effects.

Recommended Endpoints

• Essential: Lung hydroxyproline content (collagen quantification), Ashcroft score (histological fibrosis grading), pulmonary function testing (dynamic compliance via FlexiVent or equivalent)
• Recommended: Lung tissue cAMP levels (pharmacodynamic marker of PDE4B inhibition), BAL fluid cytokine profiling (TNF-alpha, IL-6, etc.), alpha-SMA immunostaining (quantification of myofibroblast differentiation)
• Exploratory: Ex vivo fibrosis assessment using PCLS (precision-cut lung slices). Human IPF-derived PCLS can minimize species-difference confounders in efficacy evaluation.

Model Selection Considerations

The bleomycin model has a tendency toward spontaneous resolution, making careful selection of assessment timepoints and adequate group sizes essential. Complementary models — such as silica-induced or AAV-TGF-beta models that produce more sustained fibrosis — are also worth considering. The chronic fibrosis progression pattern of the silica model is particularly suited for evaluating sustained efficacy under prolonged dosing.

Summary

Nerandomilast (Jascayd) has overcome the longstanding tolerability barrier of PDE4 inhibitors through the precision of PDE4B-selective molecular design, delivering a genuinely new treatment option for IPF. The add-on benefit demonstrated in the FIBRONEER-IPF trial fundamentally expands the therapeutic landscape for patients with IPF. In preclinical research, adopting a therapeutic dosing protocol and incorporating combination study designs are the keys to capturing the true pharmacological potential of PDE4B inhibitors.

---

Related Articles

• IPF Treatment Landscape 2025 -- A panoramic view of the IPF drug pipeline, from approved therapies to emerging candidates.
• Inhaled Treprostinil (Tyvaso): TETON-1/2 Results in IPF -- The next sNDA candidate with a mechanism complementary to Nerandomilast; the backbone of upcoming combination therapy.
• LPA1 Receptor Antagonist BMS-986278 -- Mechanism and clinical data for another promising IPF pipeline candidate.
• IPF vs. PPF: Classifying Progressive Fibrosis and Treatment Strategies -- How pathophysiological differences between IPF and PPF shape treatment decisions.
• Pitfalls of the Bleomycin Pulmonary Fibrosis Model -- Commonly overlooked considerations in preclinical model design.
• PCLS (Precision-Cut Lung Slices) for Ex Vivo Fibrosis Assessment -- Human tissue-based evaluation systems that complement animal models.

References

1. Richeldi L, et al. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022;386(23):2178-2187. PubMed
2. Richeldi L, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF). N Engl J Med. 2025;392(17):1617-1628. PubMed
3. Hatzelmann A, et al. The preclinical pharmacology of roflumilast -- a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235-256. PubMed
4. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511. PubMed
5. Flaherty KR, et al. Nintedanib in progressive fibrosing interstitial lung diseases (INBUILD). N Engl J Med. 2019;381(18):1718-1727. PubMed
6. FDA News Release. FDA approves Jascayd (nerandomilast) for treatment of idiopathic pulmonary fibrosis. October 7, 2025. FDA.gov
7. European Medicines Agency. Medicines for human use under evaluation -- nerandomilast (EMEA/H/C/006405). EMA.europa.eu
8. Boehringer Ingelheim. U.S. FDA approves JASCAYD (nerandomilast) for progressive pulmonary fibrosis (corporate communication noting ongoing regulatory submissions in additional geographies). December 19, 2025. boehringer-ingelheim.com